Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis - Wikidata - wikimedia - TriplyDB

Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis

Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis

http://www.wikidata.org/entity/Q28377349

about

Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance P Isolation of Aspergillus spp. from the respiratory tract in critically ill patients: risk factors, clinical presentation and outcome.Potential Use of Phenolic Acids as Anti-Candida Agents: A Review Pharmacokinetics and pharmacodynamics of antifungals in children: clinical implications Efficient clearance of Aspergillus fumigatus in murine lungs by an ultrashort antimicrobial lipopeptide, palmitoyl-lys-ala-DAla-lys Practice guidelines for lipid-based amphotericin B in stem cell transplant recipients.Pharmacological advances in the treatment of invasive candidiasis.Pre-medication practices and incidence of infusion-related reactions in patients receiving AMPHOTEC: data from the Patient Registry of Amphotericin B Cholesteryl Sulfate Complex for Injection Clinical Tolerability (PRoACT) registry.Changes in the proteome of Candida albicans in response to azole, polyene, and echinocandin antifungal agents.Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis Cost-effectiveness of posaconazole versus fluconazole or itraconazole in the prevention of invasive fungal infections among high-risk neutropenic patients in Spain.Comparative drug disposition, urinary pharmacokinetics, and renal effects of multilamellar liposomal nystatin and amphotericin B deoxycholate in rabbits Nanopharmaceuticals (part 1): products on the market.Practice guidelines for the diagnosis and management of skin and soft-tissue infections.Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.The incidence and prognostic significance of acute kidney injury.Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model Expert opinion on pharmacotherapy of kidney disease in HIV-infected patients.Fungicidal synergism of fluconazole and cyclosporine in Candida albicans is not dependent on multidrug efflux transporters encoded by the CDR1, CDR2, CaMDR1, and FLU1 genes.Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis Therapeutic monitoring of amphotericin B in Saudi ICU patients using UPLC MS/MS assay.Recommendations for the treatment of fungal pneumonias.Systemic antifungal therapy: new options, new challenges.Invasive aspergillosis in patients with hematologic malignancies.New and emerging antifungal agents: impact on respiratory infections.Once-weekly micafungin therapy is as effective as daily therapy for disseminated candidiasis in mice with persistent neutropenia Management of infectious complications in the hematopoietic stem cell transplant recipient.Changing strategies for the management of invasive fungal infections.Guidelines for the use of antifungal agents in the treatment of invasive Candida and mould infections.Management of opportunistic infections in solid-organ transplantation.Recent advances in antifungal pharmacotherapy for invasive fungal infections.Management of invasive pulmonary aspergillosis in non-neutropenic critically ill patients Experience with community-based amphotericin B infusion therapy.An economic evaluation of voriconazole versus amphotericin B for the treatment of invasive aspergillosis in Canada.Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes.Antiretroviral therapy and the kidney: balancing benefit and risk in patients with HIV infection.Emerging echinocandins for treatment of invasive fungal infections.Brief Report: Effects of Tenofovir and Amphotericin B Deoxycholate Coadministration on Kidney Function in Patients Treated for Cryptococcal Meningitis David and Goliath: chemical perturbation of eukaryotes by bacteria.The safety of anidulafungin.

P2860

Q24535844-2D1DAF2A-D52B-4B0E-B109-590F9D33432A Q24811601-06F1F38E-80A6-4678-83FA-657E8F0D8242 Q26770692-07F863BC-606F-467C-9949-C31D2A05B812 Q27025299-538CBF1B-6572-4889-958B-11B153B27544 Q31161843-985D6EE5-F097-4F15-9309-3208D4780FED Q32052950-0F00DB96-1BFC-4E49-95D5-0EE2D55671AA Q33232599-0F8E107B-3E8C-4ECE-A4DD-7359B8D0F6FC Q33371455-2E7489D5-7C41-4BAA-A5E2-D18BFF6DE079 Q33530441-A0CBFAB7-917A-4FBF-ABBF-C8D7E2C62A69 Q34045435-3D87774B-BF14-49FD-B7C2-047F53BF014E Q34218399-768AEB1D-2E76-4AA7-9055-6DC7C9D02002 Q34229980-DD2D27BD-5FC8-4C38-9052-4A7395A25F6A Q34230175-94559B98-882D-4C51-9170-6579D7A83E07 Q34460523-3722EB4C-A3B8-4BE1-85B5-238894C8791B Q34505582-5F1C1A27-A582-4AA6-82A2-02147006CDE4 Q34523413-AF8EC958-8C91-4554-B08C-C661E9469122 Q34680675-EFFCA38B-EFB2-4C9A-B4AA-4C8AB2C30183 Q34686870-1A8069BA-BE95-4C0C-8B29-033CD34F6FE1 Q34939981-680A7275-B65A-4C0F-8400-B5802859A9F6 Q35127833-F1AB8E00-A429-49F8-A120-772D71C6E29D Q35148135-F1EA278F-D2E6-4F46-AED4-42FFF90A4445 Q35183728-0796E1BA-A120-4861-956B-3AD4F4F2A786 Q35585219-4ED712C3-2E2A-45AE-9E3F-1712E4CF3548 Q35616161-4FF2ACBA-B841-409A-9892-6E4476364D31 Q35627629-F11047F8-35AE-419C-9BC3-0B3B6E24816F Q35647785-E4C6F2C5-70F9-4570-BD65-72F1D10566F6 Q35675979-3039AD6B-8521-44A6-AE66-B27226D67070 Q35678997-84E70F31-6BA2-4FDD-BA21-A6BA26F32D19 Q35746695-6124B7B7-9F5F-4E9B-9E11-4C53D93BA63D Q35841369-6482A8D4-C323-4680-B552-D97F8C6FB24E Q35917383-8B2B3C18-ADD8-4558-8ECF-E34E20B0110D Q36087577-33860AF4-3E71-444E-876A-A2E1FD609538 Q36130619-5DC28A20-0079-4FFF-A542-9B3CAC2EEC13 Q36170887-875B349C-5831-485A-A695-E43B903D086F Q36383044-8A0ED497-07CC-42A4-AEDD-0821BB464470 Q36407276-9E3F667A-48B8-4F2B-9BDC-EE004104E8FD Q36458402-8320AD29-4318-4036-BFE3-1B0132EB1D17 Q36463811-8BC9E795-7095-436A-8619-6C4E3B1C3319 Q36577080-1654A0F6-CA62-4EDD-8DF3-59CCF4BD9FC1 Q36624970-8AD473B9-0064-4CA2-A7AF-5ED99A9102DD

P2860

Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis

http://www.wikidata.org/entity/Q28377349

description

1999 nî lūn-bûn

@nan

1999 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Clinical significance of nephr ...... pected or proven aspergillosis

@ast

Clinical significance of nephr ...... pected or proven aspergillosis

@en

Clinical significance of nephr ...... pected or proven aspergillosis

@nl

type

label

Clinical significance of nephr ...... pected or proven aspergillosis

@ast

Clinical significance of nephr ...... pected or proven aspergillosis

@en

Clinical significance of nephr ...... pected or proven aspergillosis

@nl

prefLabel

Clinical significance of nephr ...... pected or proven aspergillosis

@ast

Clinical significance of nephr ...... pected or proven aspergillosis

@en

Clinical significance of nephr ...... pected or proven aspergillosis

@nl

P1433

Q28377349-9A595AA5-F642-4A69-B63A-3FFC67D23B33

P1476

Q28377349-FDDB5F29-684F-4760-94D5-7F1FFEB5D026

P2093

Q28377349-19FD2184-BF81-42FC-B52B-46F9A4E1FD3D

Q28377349-2866E02E-E33C-43B5-99E9-8E69A0228E60

Q28377349-2AE642A9-666D-42A1-8EC4-C7162EA3D9F5

Q28377349-4A8F92CE-794E-4908-99AA-48A21F7E7A4F

Q28377349-64E47BAC-3E71-44A7-8AF9-045EBD069AE6

Q28377349-77A2AD2F-44DF-4147-B0C6-CF224E7115C5

Q28377349-98AFCF3C-728E-4021-AE96-C05B377A18A5

Q28377349-A9EAB1A8-CAB0-46CD-B66A-B6A0C7097474

Q28377349-C4CD52FB-8C7E-4359-9225-63EC67803A54

Q28377349-F06ACBB0-15E3-4E23-9CE6-73C38C3BA0D8

P304

Q28377349-06FC6D79-B371-4316-8A90-655F60AAA0E9

P31

Q28377349-DAEADFA9-DF00-49F0-9DC7-24C491A087C9

P3181

Q28377349-2789D060-ADE1-46D5-93A8-053C26D117E8

P356

Q28377349-24355F13-C58A-4695-9C49-D91A42C9FD7E

P407

Q28377349-10C2455E-8DAB-4A29-950E-7C7D4DC002FB

P433

Q28377349-0F04EC0B-B2EC-4E2E-8CEA-E671805F07B4

P478

Q28377349-42B984AF-BFF6-4589-A111-71B18E4E6620

P577

Q28377349-43EB1325-2103-4050-879A-7BD25970CF84

P5875

Q28377349-9714AB4C-49E3-4409-8B8B-CE47365A1D71

P698

Q28377349-50B7EA78-3879-4F81-8A95-8B7D4BC4DC33

P921

Q28377349-26B6714C-C942-484F-BBB9-0943480B51C1

Q28377349-27A61538-4D9B-4616-83C5-CC9EFC0935F7

P3181

P356

P1433

Clinical Infectious Diseases

P1476

Clinical significance of nephr ...... pected or proven aspergillosis

@en

P2093

E Anaissie

http://www.w3.org/2001/XMLSchema#string

G Yee

http://www.w3.org/2001/XMLSchema#string

J Hiemenz

http://www.w3.org/2001/XMLSchema#string

J Lister

http://www.w3.org/2001/XMLSchema#string

J R Wingard

http://www.w3.org/2001/XMLSchema#string

L Lee

http://www.w3.org/2001/XMLSchema#string

L Walshe

http://www.w3.org/2001/XMLSchema#string

M White

http://www.w3.org/2001/XMLSchema#string

P Kubilis

http://www.w3.org/2001/XMLSchema#string

R Bowden

http://www.w3.org/2001/XMLSchema#string

P304

1402-7

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1305010

http://www.w3.org/2001/XMLSchema#string

P356

10.1086/313498

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P577

1999-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12715102

http://www.w3.org/2001/XMLSchema#string

P698

10585786

http://www.w3.org/2001/XMLSchema#string

P921